Table 1 Patient characteristics . Total... | American Society of Hematology

Table 1

Patient characteristics

	Total	A locus		B locus		C locus		DRB1 locus		DQB1 locus		DPB1 locus
	Total	Match	Mismatch	Match	Mismatch	Match	Mismatch	Match	Mismatch	Match	Mismatch	Match	Mismatch
	4643	4018	625	4351	292	3308	1335	3718	925	3597	1046	1584	3059
Median age, y	31.5	31.8	29.6	31.7	28.3	31.8	30.9	31.7	30.9	31.7	30.8	31.8	31.4
Sex, donor/patient
Male/male	1904	1673	231	1769	135	1387	517	1551	353	1492	412	678	1226
Male/female	923	789	134	874	49	650	273	734	189	704	219	299	624
Female/male	894	747	147	843	51	634	260	693	201	672	222	268	626
Female/female	922	809	113	865	57	637	285	740	182	729	193	339	583
Disease
ALL	1464	1267	197	1372	92	1051	413	161	303	1132	332	452	1012
AML	1571	1360	211	1478	93	1114	457	1255	316	1224	347	574	997
CML	979	827	152	905	74	682	297	779	200	746	233	343	636
ML	564	507	57	536	28	43	146	468	96	49	118	192	372
MM	65	57	8	60	5	418	22	55	10	446	16	23	42
Risk of leukemia relapse*
Standard risk	1684	1485	199	1588	96	1184	500	1375	309	1322	362	572	1112
High risk	1909	1607	302	1772	137	1365	544	1485	424	1451	458	642	1267
Disease other than leukemia	1050	926	124	991	59	759	291	858	192	824	226	370	680
GVHD prophylaxis
Cyclosporine-based	2503	2159	344	2346	157	1802	701	2107	396	2030	473	881	1622
Tacrolimus-based	2140	1859	281	2005	135	1506	634	1611	529	1567	573	703	1437
ATG
ATG	152	112	40	135	17	102	50	110	42	118	34	51	101
Non-ATG	4491	3906	585	4216	275	3206	1285	3608	883	3479	1012	1533	2958
Preconditioning
TBI regimen	3687	3175	512	3445	242	2623	1064	2933	754	2834	853	1242	2445
Non-TBI regimen	956	843	113	906	50	685	271	785	171	763	193	342	614

	Total	A locus		B locus		C locus		DRB1 locus		DQB1 locus		DPB1 locus
	Total	Match	Mismatch	Match	Mismatch	Match	Mismatch	Match	Mismatch	Match	Mismatch	Match	Mismatch
	4643	4018	625	4351	292	3308	1335	3718	925	3597	1046	1584	3059
Median age, y	31.5	31.8	29.6	31.7	28.3	31.8	30.9	31.7	30.9	31.7	30.8	31.8	31.4
Sex, donor/patient
Male/male	1904	1673	231	1769	135	1387	517	1551	353	1492	412	678	1226
Male/female	923	789	134	874	49	650	273	734	189	704	219	299	624
Female/male	894	747	147	843	51	634	260	693	201	672	222	268	626
Female/female	922	809	113	865	57	637	285	740	182	729	193	339	583
Disease
ALL	1464	1267	197	1372	92	1051	413	161	303	1132	332	452	1012
AML	1571	1360	211	1478	93	1114	457	1255	316	1224	347	574	997
CML	979	827	152	905	74	682	297	779	200	746	233	343	636
ML	564	507	57	536	28	43	146	468	96	49	118	192	372
MM	65	57	8	60	5	418	22	55	10	446	16	23	42
Risk of leukemia relapse*
Standard risk	1684	1485	199	1588	96	1184	500	1375	309	1322	362	572	1112
High risk	1909	1607	302	1772	137	1365	544	1485	424	1451	458	642	1267
Disease other than leukemia	1050	926	124	991	59	759	291	858	192	824	226	370	680
GVHD prophylaxis
Cyclosporine-based	2503	2159	344	2346	157	1802	701	2107	396	2030	473	881	1622
Tacrolimus-based	2140	1859	281	2005	135	1506	634	1611	529	1567	573	703	1437
ATG
ATG	152	112	40	135	17	102	50	110	42	118	34	51	101
Non-ATG	4491	3906	585	4216	275	3206	1285	3608	883	3479	1012	1533	2958
Preconditioning
TBI regimen	3687	3175	512	3445	242	2623	1064	2933	754	2834	853	1242	2445
Non-TBI regimen	956	843	113	906	50	685	271	785	171	763	193	342	614

ATG indicates antithymocyte globulin; and TBI, total body irradiation.

Standard risk for leukemia relapse was defined as the status of the first complete remission of AML and ALL and the first chronic phase of CML at transplant, while high risk was defined as a more advanced status than standard risk in AML, ALL, and CML. Disease other than leukemia was defined as other than ALL, AML, and CML.

View Large

This Feature Is Available To Subscribers Only